A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Ibarz-Pavon AB. et al, (2025), Vaccine, 56
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT.
Waldron C-A. et al, (2025), Health Technol Assess, 29, 1 - 125
Severe Parvovirus B19-Associated Myocarditis in Children in the Post-COVID-19 Era: A Multicenter Observational Cohort Study.
Russell N. et al, (2025), Open Forum Infect Dis, 12
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Milotay G. et al, (2025), Nature Medicine
Author Correction: Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein.
Kim YC. et al, (2025), NPJ Vaccines, 10
Influence of context on engagement with COVID-19 testing: a scoping review of barriers and facilitators to testing for healthcare workers, care homes and schools in the UK.
Andersen-Waine B. et al, (2025), BMJ Open, 15
Re-imagining combination vaccines for travel medicine
McGuinness SL. et al, (2025), Journal of Travel Medicine
A systems biology approach to define SARS-CoV-2 correlates of protection.
Brady C. et al, (2025), NPJ Vaccines, 10
Oral Swab Testing With Xpert MTB/RIF Ultra for the Diagnosis of Tuberculosis in Children Aged <5 Years in Uganda: An Exploratory Interim Analysis of Diagnostic Accuracy in the NOD-pedFEND Cohort.
Khambati N. et al, (2025), Open Forum Infect Dis, 12
Confronting the shortcomings of covid-19 vaccination will help us in future pandemics.
Vanderslott S., (2025), BMJ, 388
Absolute quantification of rare gene targets in limited samples using crude lysate and ddPCR
Kaur C. et al, (2025), Scientific Reports, 15
Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nat Commun, 16
Epidemiology of Group B Streptococcus: Maternal Colonization and Infant Disease in Kampala, Uganda
Kyohere M. et al, (2025), Open Forum Infectious Diseases
Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.
Firth C. et al, (2025), Vaccine, 54
Maternal views on RSV vaccination during the first season of implementation in England and Scotland.
Williams TC. et al, (2025), Lancet Infect Dis, 25, e135 - e136